Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026. The lawsuit alleges that Atara made false or misleading statements about manufacturing issues and regulatory risks related to its drug tabelecleucel, overstating its chances of FDA approval. These issues reportedly jeopardized clinical trials and negatively impacted Atara's business and stock value. Investors affected during this period may seek compensation by joining the lawsuit before the May 22, 2026 deadline to move for lead plaintiff status.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
TransUnion has enhanced its mortgage credit report by integrating TruVision™ Alternative Credit Attributes (ACA 2.0) from FactorTrust® to provide lenders with broader insights beyond traditional credit data. This new data helps lenders identify borro...
